What is CJC-1295 without DAC?
CJC-1295 without DAC belongs to the growth-hormone-releasing hormone family of research analogues. GHRH receptor signalling in pituitary somatotrophs sits upstream of growth hormone release, giving this class a different biological entry point from ghrelin-receptor agonists such as ipamorelin. The no-DAC designation means the albumin-reactive Drug Affinity Complex is absent.
The current Lynx documentation establishes a 29-residue peptide and D-Ala at position 2. It does not establish every substitution commonly advertised for modified GRF(1–29), so those additional sequence claims are not adopted here. Structural modifications can change enzymatic stability and receptor activity, but results for one defined analogue cannot specify another by name alone. Human duration and pulsatility findings for DAC-bearing CJC-1295 are therefore discussed on the DAC page rather than presented as measurements for this material.
Related scientific guides: CJC-1295 DAC and no-DAC structural distinctions.
CJC-1295 without DAC Research Areas
D-amino-acid substitution at position 1 or 2 protected defined GHRH preparations against cleavage by DPP-IV in plasma experiments. Native and shortened GHRH fragments were readily cleaved near the N-terminus, with additional trypsin-like degradation contributing less. This explains the interest in position-2 modifications without establishing the rest of a catalogue analogue’s sequence.
Frohman et al. · J Clin Invest · 1989PubMed
Mass spectrometry identified an amidated 29-residue peptide in a preparation marketed as CJC-1295. The proposed sequence arose from analysis of that particular sample. The finding demonstrates how molecular identity can be examined; it does not establish the complete sequence of every material sold under the same name.
Henninge et al. · Drug Test Anal · 2010PubMed
Molecular profile
- Compound
- CJC-1295 without DAC
- Amount
- 5 mg
- Sequence
- Tyr-D-Ala-
Asp-Ala- Ile-Phe- Thr-Gln- Ser-Tyr- Arg-Lys- Val-Leu- Ala-Gln- Leu-Ser- Ala-Arg- Lys-Leu- Leu-Gln- Asp-Ile- Leu-Ser-Arg-NH₂ - Residue count
- 29
- Molecular formula
- C152H252N44O42
- Molecular weight
- 3358.0 g/mol
- Chemical class
- Synthetic GHRH analogue without DAC
- Classification
- Research peptide
- Parent molecule
- CJC-1295 without DAC / Modified GRF(1-29)
- Available vial sizes
- 5 mg
Analytical verification
- Lynx report reference
- UKLY-692
- Reported purity
- 98.835%
- Analysis method
- RP-HPLC + ESI-MS
- Identity result
- Confirmed: CJC-1295 no DAC
- Analysis date
- 3 Sept 2026
- Report date
- 3 Sept 2026
Storage & Reconstitution
Store in appropriate cool, dry conditions. Refer to product-specific storage information when published.
Vials are supplied separately from bacteriostatic water and other preparation supplies.
For laboratory handling context, read Research peptide storage and stability. Product-specific information and the laboratory method take precedence.
For laboratory preparation, allow the sealed vial to reach room temperature before opening. Wipe the vial stopper and bacteriostatic-water stopper with an alcohol wipe. Add bacteriostatic water slowly down the inside wall of the vial, then swirl gently until dissolved. Do not shake.
Research literature
- Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation.Henninge et al. · Drug Test Anal · 2010PubMed
- Potent long-acting growth hormone releasing factor analogues.Rivier et al. · Ann N Y Acad Sci · 1988PubMed
- Dipeptidylpeptidase IV and trypsin-like enzymatic degradation of human growth hormone-releasing hormone in plasma.Frohman et al. · J Clin Invest · 1989PubMed
CJC-1295 without DAC Price (UK)
CJC-1295 without DAC is supplied in 5 mg vials for laboratory research. The current price is £25.99.
Current availability is shown below. UK orders of £49.99 or more qualify for free standard shipping. Eligible working-day orders placed before 4 PM are dispatched the same day.
| Vial size | Current price | Price / mg | Status |
|---|---|---|---|
| 5 mg | £25.99 | £5.20/mg | Checking stock |
Common questions about CJC-1295 without DAC
What is CJC-1295 without DAC?
CJC-1295 without DAC is a synthetic analogue of growth hormone-releasing hormone, studied through the GHRH receptor pathway. The product profile lists 29 amino acids. Unlike the with-DAC version, it lacks the albumin-binding feature that changes persistence in circulation, so the two forms are distinguished by their molecular design rather than vial size.
What does ‘without DAC’ mean?
DAC stands for Drug Affinity Complex, the feature designed to bind the with-DAC peptide to albumin, a blood protein. Without DAC means that feature is absent. This matters in research because albumin binding changes how long a peptide remains in circulation; results from the with-DAC form cannot simply describe the version without it.
How does CJC-1295 without DAC differ from the with-DAC product?
The with-DAC analogue has a modification that allows albumin binding and changes its time in circulation. The without-DAC product lacks that feature, even though both belong to the GHRH analogue family. Researchers distinguish receptor activity from persistence: acting through a similar pathway does not mean two peptide forms have the same exposure profile.
How does CJC-1295 differ from Ipamorelin?
CJC-1295 is a GHRH analogue, while Ipamorelin acts through the ghrelin receptor. Both are associated with growth-hormone signalling, but they reach it through different receptor systems. That makes them useful to distinguish experimentally: a shared downstream measurement can result from different upstream signals, rather than two interchangeable versions of one compound.
Is CJC-1295 without DAC the same as the CJC-1295 + Ipamorelin blend?
No. This vial supplies the CJC component alone; the blend combines 5mg CJC-1295 without DAC with 5mg Ipamorelin. Ipamorelin adds the ghrelin-receptor pathway to the GHRH-related research of CJC-1295. A single-compound vial allows that pathway to be examined separately, while the blend keeps both components at a fixed ratio.
What is GHRH in CJC-1295 research?
GHRH is growth hormone-releasing hormone, a signal that acts at receptors on pituitary cells. CJC-1295 is an analogue studied through that pathway. The receptor is the starting point, while growth-hormone release is a downstream measurement; separating those steps helps explain why receptor activity and a hormone response are related but different findings.
Can I buy CJC-1295 without DAC in the UK for research?
Yes. The without-DAC version is listed by Lynx as a 5mg research vial for UK laboratories. Its current stock status appears on the product page.
Is CJC-1295 without DAC batch tested?
UKLY-692 shows 98.835% purity for the 5mg CJC-1295 without DAC sample, tested by RP-HPLC + ESI-MS.
